Alexandre Joosten1, Brenton Alexander2, Jacques Duranteau3, Fabio Silvio Taccone4, Jacques Creteur4, Jean-Louis Vincent4, Maxime Cannesson5, Joseph Rinehart6. 1. Department of Anesthesiology and Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium; Department of Anesthesiology and Intensive Care, Hôpitaux Universitaires Paris-Sud, Université Paris-Sud, Université Paris-Saclay, Hôpital De Bicêtre, Assistance Publique Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France. Electronic address: Alexandre.Joosten@erasme.ulb.ac.be. 2. Department of Anesthesiology, University of California-San Diego, San Diego, CA, USA. 3. Department of Anesthesiology and Intensive Care, Hôpitaux Universitaires Paris-Sud, Université Paris-Sud, Université Paris-Saclay, Hôpital De Bicêtre, Assistance Publique Hôpitaux de Paris (AP-HP), Le Kremlin-Bicêtre, France. 4. Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium. 5. Department of Anesthesiology & Perioperative Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA. 6. Department of Anesthesiology & Perioperative Care, University of California-Irvine, Irvine, CA, USA.
Abstract
BACKGROUND: Vasopressor agents are used to prevent intraoperative hypotension and ensure adequate perfusion. Vasopressors are usually administered as intermittent boluses or manually adjusted infusions, but this practice requires considerable time and attention. We have developed a closed-loop vasopressor (CLV) controller to correct hypotension more efficiently. Here, we conducted a proof-of-concept study to assess the feasibility and performance of CLV control in surgical patients. METHODS: Twenty patients scheduled for elective surgical procedures were included in this study. The goal of the CLV system was to maintain MAP within 5 mm Hg of the target MAP by automatically adjusting the rate of a norepinephrine infusion using MAP values recorded continuously from an arterial catheter. The primary outcome was the percentage of time that patients were hypotensive, as defined by a MAP of 5 mm Hg below the chosen target. Secondary outcomes included the total dose of norepinephrine, percentage of time with hypertension (MAP>5 mm Hg of the chosen target), raw percentage "time in target" and Varvel performance criteria. RESULTS: The 20 subjects (median age: 64 years [52-71]; male (35%)) underwent elective surgery lasting 154 min [124-233]. CLV control maintained MAP within ±5 mm Hg of the target for 91.6% (85.6-93.3) of the intraoperative period. Subjects were hypotensive for 2.6% of the intraoperative period (range, 0-8.4%). Additional performance criteria for the controller included mean absolute performance error of 2.9 (0.8) and mean predictive error of 0.5 (1.0). No subjects experienced major complications. CONCLUSIONS: In this proof of concept study, CLV control minimised perioperative hypotension in subjects undergoing moderate- or high-risk surgery. Further studies to demonstrate efficacy are warranted. TRIAL REGISTRY NUMBER: NCT03515161 (ClinicalTrials.gov).
BACKGROUND: Vasopressor agents are used to prevent intraoperative hypotension and ensure adequate perfusion. Vasopressors are usually administered as intermittent boluses or manually adjusted infusions, but this practice requires considerable time and attention. We have developed a closed-loop vasopressor (CLV) controller to correct hypotension more efficiently. Here, we conducted a proof-of-concept study to assess the feasibility and performance of CLV control in surgical patients. METHODS: Twenty patients scheduled for elective surgical procedures were included in this study. The goal of the CLV system was to maintain MAP within 5 mm Hg of the target MAP by automatically adjusting the rate of a norepinephrine infusion using MAP values recorded continuously from an arterial catheter. The primary outcome was the percentage of time that patients were hypotensive, as defined by a MAP of 5 mm Hg below the chosen target. Secondary outcomes included the total dose of norepinephrine, percentage of time with hypertension (MAP>5 mm Hg of the chosen target), raw percentage "time in target" and Varvel performance criteria. RESULTS: The 20 subjects (median age: 64 years [52-71]; male (35%)) underwent elective surgery lasting 154 min [124-233]. CLV control maintained MAP within ±5 mm Hg of the target for 91.6% (85.6-93.3) of the intraoperative period. Subjects were hypotensive for 2.6% of the intraoperative period (range, 0-8.4%). Additional performance criteria for the controller included mean absolute performance error of 2.9 (0.8) and mean predictive error of 0.5 (1.0). No subjects experienced major complications. CONCLUSIONS: In this proof of concept study, CLV control minimised perioperative hypotension in subjects undergoing moderate- or high-risk surgery. Further studies to demonstrate efficacy are warranted. TRIAL REGISTRY NUMBER: NCT03515161 (ClinicalTrials.gov).
Authors: Jilles B Bijker; Suzanne Persoon; Linda M Peelen; Karel G M Moons; Cor J Kalkman; L Jaap Kappelle; Wilton A van Klei Journal: Anesthesiology Date: 2012-03 Impact factor: 7.892
Authors: Daniel I Sessler; Christian S Meyhoff; Nicole M Zimmerman; Guangmei Mao; Kate Leslie; Skarlet M Vásquez; Packianathaswamy Balaji; Jesús Alvarez-Garcia; Alexandre B Cavalcanti; Joel L Parlow; Prashant V Rahate; Manfred D Seeberger; Bruno Gossetti; S A Walker; Rajendra K Premchand; Rikke M Dahl; Emmanuelle Duceppe; Reitze Rodseth; Fernando Botto; P J Devereaux Journal: Anesthesiology Date: 2018-02 Impact factor: 7.892
Authors: T W Schnider; C F Minto; S L Shafer; P L Gambus; C Andresen; D B Goodale; E J Youngs Journal: Anesthesiology Date: 1999-06 Impact factor: 7.892
Authors: C F Minto; T W Schnider; T D Egan; E Youngs; H J Lemmens; P L Gambus; V Billard; J F Hoke; K H Moore; D J Hermann; K T Muir; J W Mandema; S L Shafer Journal: Anesthesiology Date: 1997-01 Impact factor: 7.892
Authors: Joseph Rinehart; Brenton Alexander; Yannick Le Manach; Christoph Hofer; Benoit Tavernier; Zeev N Kain; Maxime Cannesson Journal: Crit Care Date: 2011-11-23 Impact factor: 9.097
Authors: Jean-Louis Vincent; Nathan D Nielsen; Nathan I Shapiro; Margaret E Gerbasi; Aaron Grossman; Robin Doroff; Feng Zeng; Paul J Young; James A Russell Journal: Ann Intensive Care Date: 2018-11-08 Impact factor: 6.925
Authors: Sean Coeckelenbergh; Cedrick Zaouter; Brenton Alexander; Maxime Cannesson; Joseph Rinehart; Jacques Duranteau; Philippe Van der Linden; Alexandre Joosten Journal: J Anesth Date: 2019-09-25 Impact factor: 2.078
Authors: Alexandre Joosten; Sean Coeckelenbergh; Brenton Alexander; Maxime Cannesson; Joseph Rinehart Journal: Anaesth Crit Care Pain Med Date: 2020-04-05 Impact factor: 4.132
Authors: Alexandre Joosten; Joseph Rinehart; Philippe Van der Linden; Brenton Alexander; Christophe Penna; Jacques De Montblanc; Maxime Cannesson; Jean-Louis Vincent; Eric Vicaut; Jacques Duranteau Journal: Anesthesiology Date: 2021-08-01 Impact factor: 8.986
Authors: Alexandre Joosten; Dragos Chirnoaga; Philippe Van der Linden; Luc Barvais; Brenton Alexander; Jacques Duranteau; Jean-Louis Vincent; Maxime Cannesson; Joseph Rinehart Journal: Br J Anaesth Date: 2020-10-08 Impact factor: 9.166
Authors: Alexandre Joosten; Sean Coeckelenbergh; Brenton Alexander; Amélie Delaporte; Maxime Cannesson; Jacques Duranteau; Bernd Saugel; Jean-Louis Vincent; Philippe Van der Linden Journal: BMC Anesthesiol Date: 2020-08-20 Impact factor: 2.217